The Scientific Advisory Group (SAG) has been called in to assist the EMA’s CHMP human medicines committee in its review of the drug, which is vying to become the first disease-modifying therapy ...
The CHMP has issued a positive opinion for the drug as a treatment for adults with insufficiently controlled type 2 diabetes, to improve glycaemic control as an adjunct to diet and exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback